Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Publications

Joint event with World Economic Forum on the evolving role of generics – Meeting Report

On 24 May 2023, the Access to Medicine Foundation and the World Economic Forum (WEF) organised a dialogue to discuss the role of the generics and biosimilars industry in ensuring equitable access to medicines globally, along the sidelines of the 76th World Health Assembly in Geneva. The summary of the discussion has been captured in a meeting report, which is now available for download.

Date

21 June 2023

Download the Meeting Report

Almost 60 high-level participants joined this interactive discussion, including CEOs, experts involved in developing and/or producing medicines, policymakers from government, representatives from non-profit implementing organisations, and regulators. Several leading manufacturers based in low- and middle-income countries (LMICs) were also in attendance, and articulated their readiness to join forces to address the problem of access and build health system resilience to withstand future shocks.  

The participants considered the evolving role of generics and biosimilars manufacturers and partners in ensuring the equitable supply of essential medicines in LMICs.

High-level themes 

As explored in more detail in the meeting report, participants shared insights and solutions related to these key topics:

  1. Expanding the local manufacturing pool: establishing resilience; meeting future demand; investing in domestic markets; voluntary licensing; technology transfers; and harmonisation of regulation.

  2. Building domestic health system and regulatory capacity: regional harmonisation; regulatory pathways in LMICs; legal and regulatory preparedness for future pandemics and global emergencies; and building capacity by training healthcare professionals and inspectors – particularly in the biosimilars sector.

  3. Ensuring equitable access to quality assured products: prioritising access to medicine; strengthening regulatory systems and quality assurance regimes to tackle low-quality, falsified or substandard medicines; and ensuring that quality – not just price – is central to tendering decisions.

  4. Increasing political willpower: seeking a global solution tailored to local needs; and the need for parliamentarians from different countries to advocate for better access.  

  5.  Action vs. ideology: how to translate ideological commitments to equity into equitable market-based solutions built to last; how to deploy tactical solutions (e.g. coordinated and pooled procurement, tech transfer) systematically and intentionally.

Calls to action

Participants emphasised the need for action now, rather than later. Based on this discussion, the co-hosts of the event – the Access to Medicine Foundation and the World Economic Forum – have identified priorities for action by major stakeholders in public health, including:

  1. Public sector stakeholders (government, policymakers, civil society, and non-governmental agencies) 

  1. Private sector stakeholders, particularly manufacturers

  1. Investors and donors 

  1. Procurers 

  1. Regulatory authorities  

Specific calls-to-action for each stakeholder are included in the full meeting report.

The Generic & Biosimilar Medicines Programme

Insights from the discussion will be used to inform the Access to Medicine Foundation's Generic & Biosimilar Medicines Programme, which seeks to stimulate and guide generic and biosimilar medicine manufacturers to expand access to their products in LMICs. As part of this programme, the Foundation has previously convened a workshop, and has created a first-of-its-kind analytical framework to evaluate companies.

Later in 2023, the Foundation will publish a first analysis – carried out using this analytical framework – of how five of the leading generic and biosimilar medicine manufacturers are leveraging their know-how, broad manufacturing footprint and technical expertise to make their products more available, accessible, and affordable in LMICs.

Claudia Martínez

Director of Research

cmartinez@accesstomedicinefoundation.org

Get in touch

Sectors and research

Learn more about our Generic & Biosimilar Medicines Programme
News

First-of-its-kind framework to assess how generics manufacturers expand access to medicine

15 February 2023
Media

Poor countries desperately need better access to generic medicines

15 February 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved